Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast -2023 - EU5

Publisher Name :
Date: 01-Jan-2017
No. of pages: 75
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023-EU5" Report provides an overview of the disease and market size of the CMV for the EU5 (France, Germany, Italy, Spain and United Kingdom) for 2013-2023. It also includes historical and forecast edepidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infants Patients at High Risk of CMV and HIV Patients at High Risk of CMV from 2013-2023.

According to DelveInsight, the total number of Diagnosed Cytomegalovirus (CMV) infection cases in France is expected to increase at a CAGR of 0.06% to 20,871 cases by 2023. In case of Germany it is expected to increase at a CAGR of 0.067% to 21,619 cases by 2023. In United Kingdom, the total number of Diagnosed Cytomegalovirus (CMV) infection cases is expected to increase at a CAGR of 0.061% to 14,417 cases by 2023 and in Spain is expected to increase at a CAGR of 0.029% to 12,810 cases in 2023. For Italy, it is expected to increase at a CAGR of 0.031% to 13,358 cases in 2023. CMV infection is most prevalent in Italy and least prevalent in Spain of the EU5.

As per DelveInsight's estimation, the market size of Cytomegalovirus (CMV) infection shall reach to USD 50.2 Million in Italy, USD 213.3 Million in Germany, USD 142.3 Million in France, USD 62.8 Million in Spain and USD 63.8 Million in United Kingdom by the end of 2023. Italy has the lowest and Germany has the highest market size of the EU5.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.

- Marketed information including available prescription drugs.

- The Report also covers the detailed historical and forecasted epidemiological data covering Spain, Italy, United Kingdom, Germany, and France from 2013-2023.

- It also provides Market size of Cytomegalovirus (CMV) infection for Spain, Italy, United Kingdom, Germany, and France from 2013 and forecasted Market size to 2023.

Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast -2023 - EU5

Table of Contents

Cytomegalovirus Infections
Disease Overview
Symptoms of cytomegalovirus (CMV) Infection
Etiology
Risk Factors
Pathogenesis of human cytomegalovirus
Pathophysiology of cytomegalovirus infection
Diagnosis
Treatment Algorithm for Cytomegalovirus Infections
Treatment for Congenital CMV Infection
Treatment of Ganciclovir resistant CMV
Treatment Guidelines
Recommendations for Treating Cytomegalovirus Infections
Disease Management
Epidemiology and Patient Population
Europe
Assumptions and Rationale
Italy
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Spain
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
United Kingdom
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Germany
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
France
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Unmet Medical Needs
Marketed Products
Valcyte (Valganciclovir hydrochloride)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
FOSCAVIR (foscarnet sodium)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
CytoGam (Cytomegalovirus Immune Globulin Intravenous-Human)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
CytoTect CP
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
Valtrex (Valacyclovir hydrochloride)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
Emerging Products Analysis
Emerging Therapies
1. Approved Products
Cytovir CMV: Cell Medica Ltd.
Product Description
Research and Development
Product Development Activities
2. Pipeline Products (Phase III)
CytoTect CP 70: Biotest AG.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Letermovir: Merck & Co.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Brincidofovir: Chimerix Inc.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
ASP0113: Astellas Pharma Global Development, Inc.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Human Cytomegalovirus Immune Globulin: CSL Behring
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Europe Market Size
Italy
Germany
France
Spain
United Kingdom
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

List of Tables

Table 1: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy (2013-2023)
Table 2: CMV Patients among Transplants in Italy (2013-2023)
Table 3: Infants Patients at High Risk of CMV in Italy (2013-2023)
Table 4: HIV Patients at High Risk of CMV in Italy (2013-2023)
Table 5: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain (2013-2023)
Table 6: CMV Patients among Transplants in Spain (2013-2023)
Table 7: Infants Patients at High Risk of CMV in Spain (2013-2023)
Table 8: HIV Patients at High Risk of CMV in Spain (2013-2023)
Table 9: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom (2013-2023)
Table 10: CMV Patients among Transplants in United Kingdom (2013-2023)
Table 11: Infants Patients at High Risk of CMV in United Kingdom (2013-2023)
Table 12: HIV Patients at High Risk of CMV in United Kingdom (2013-2023)
Table 13: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany (2013-2023)
Table 14: CMV Patients among Transplants in Germany (2013-2023)
Table 15: Infants Patients at High Risk of CMV in Germany (2013-2023)
Table 16: HIV Patients at High Risk of CMV in Germany (2013-2023)
Table 17: Total CMV Prevalent, Diagnosed and Treatable Cases for France (2013-2023)
Table 18: CMV Patients among Transplants in France (2013-2023)
Table 19: Infants Patients at High Risk of CMV in France (2013-2023)
Table 20: HIV Patients at High Risk of CMV in France (2013-2023)
Table 21: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 22: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 23: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 24: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 25: Total Market size of Cytomegalovirus (CMV) Infection USD, Million (2013-2023)

List of Figures

Figure 1: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy (2013-2023)
Figure 2: CMV Patients among Transplants in Italy (2013-2023)
Figure 3: Infants Patients at High Risk of CMV in Italy (2013-2023)
Figure 4: HIV Patients at High Risk of CMV in Italy (2013-2023)
Figure 5: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain (2013-2023)
Figure 6: CMV Patients among Transplants in Spain (2013-2023)
Figure 7: Infants Patients at High Risk of CMV in Spain (2013-2023)
Figure 8: HIV Patients at High Risk of CMV in Spain (2013-2023)
Figure 9: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom (2013-2023)
Figure 10: CMV Patients among Transplants in United Kingdom (2013-2023)
Figure 11: Infants Patients at High Risk of CMV in United Kingdom (2013-2023)
Figure 12: HIV Patients at High Risk of CMV in United Kingdom (2013-2023)
Figure 13: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany (2013-2023)
Figure 14: CMV Patients among Transplants in Germany (2013-2023)
Figure 15: Infants Patients at High Risk of CMV in Germany (2013-2023)
Figure 16: HIV Patients at High Risk of CMV in Germany (2013-2023)
Figure 17: Total CMV Prevalent, Diagnosed and Treatable Cases for France (2013-2023)
Figure 18: CMV Patients among Transplants in France (2013-2023)
Figure 19: Infants Patients at High Risk of CMV in France (2013-2023)
Figure 20: HIV Patients at High Risk of CMV in France (2013-2023)
Figure 21: Total Market Size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
Figure 22: US Market Size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
Figure 23: Italy market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
Figure 24: Germany market size of Cytomegalovirus (CMV) Infection in USD, Million (2013-2023)
Figure 25: France market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • Efficacy of Stand-alone Power Sources Drive The Global Distributed Energy Generation Market
    The global market for distributed energy generation is expected to magnify at a momentous CAGR of 11.4% between 2016 and 2020. The small-scale generation of electricity, oscillating from a few kilowatts to multitudes of megawatts, is denoted as distributed energy generation. In this process, power is usually produced using renewable resources or by generators during consumption. [...]
  • Global Organic Food Market Makes A Mark in Developed Economies
    Buyers throughout the world are becoming more and more health cognizant, which has occasioned in an alteration in their palates and inclinations. The global organic food market was worth US$88.1 billion in 2015 is anticipated to record a CAGR of over 16% between 2015 and 2020. Amongst the various different food products available, the fruits [...]
  • Global Cefazolin Sodium Market Professional Survey Report 2017
    Published: 13-Jan-2017        Price: US 3500 Onwards        Pages: 125
    Notes: Production, means the output of Cefazolin Sodium Revenue, means the sales value of Cefazolin Sodium This report studies Cefazolin Sodium in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market......
  • Global Cefazolin Sodium Sales Market Report 2017
    Published: 11-Jan-2017        Price: US 4000 Onwards        Pages: 118
    Notes: Sales, means the sales volume of Cefazolin Sodium Revenue, means the sales value of Cefazolin Sodium This report studies sales (consumption) of Cefazolin Sodium in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Acs Dobfar spa - Fresenius Kabi Anti-Infectives - Olon - Orchid......
  • Global Clotrimazole Market Professional Survey Report 2017
    Published: 10-Jan-2017        Price: US 3500 Onwards        Pages: 124
    Notes: Production, means the output of Clotrimazole Revenue, means the sales value of Clotrimazole This report studies Clotrimazole in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for e......
  • Global Clotrimazole Market Research Report 2017
    Published: 03-Jan-2017        Price: US 2900 Onwards        Pages: 110
    Notes: Production, means the output of Clotrimazole Revenue, means the sales value of Clotrimazole This report studies Clotrimazole in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering - Bayer - Erregierre - F.I.S. - Amoli Organics - CordenPharma - ......
  • Aspergillosis-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Aspergillosis-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Aspergillosis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, f......
  • Shigella Infections (Shigellosis)-API Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • Escherichia Coli Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Escherichia Coli Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Escherichia Coli Infections Report is to understand the market and pipeline status of the drugs around the Escherichia Coli Infections to explore the generic development opportunities, licensing opportunities an......
  • Fungal Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Fungal Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Fungal Infections Report is to understand the market and pipeline status of the drugs around the Fungal Infections to explore the generic development opportunities, licensing opportunities and to gain competitive advantag......
  • Mycamine -Drug Insights, 2017
    Published: 01-Jan-2017        Price: US 1000 Onwards        Pages: 35
    DelveInsight Drug Report, "Mycamine- Drug Insights, 2017" highlights the Mycamine marketed details, pipeline status and the Global API Manufacturers along with the location. The DelveInsight's report covers the Global Market Assessment of the Mycamine covering the total sales estimation and also provides the Mycamine sales performance during the historical period and forecast period to 2018. DelveInsight's Report also covers the detailed clinical assessment of Mycamine, patents information and e......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs